Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Debt / NOTE 1.000% 8/1
-
Market price (% of par)
-
97.4%
-
Total 13F principal
-
$623,774,400
-
Principal change
-
-$31,761,600
-
Total reported market value
-
$607,993,350
-
Number of holders
-
70
-
Value change
-
-$28,940,823
-
Number of buys
-
24
-
Number of sells
-
35
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 as of Q1 2024
As of 31 Mar 2024,
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 was held by
70 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$623,774,400
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, Calamos Advisors LLC, WOLVERINE ASSET MANAGEMENT LLC, ADVENT CAPITAL MANAGEMENT /DE/, MACKAY SHIELDS LLC, LAZARD ASSET MANAGEMENT LLC, CAMDEN ASSET MANAGEMENT L P /CA, Mirabaud Asset Management (France) SAS, Polar Asset Management Partners Inc., and Magnetar Financial LLC.
This page lists
70
institutional bondholders reporting positions
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.